Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

EGX:RMDA Revenue

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had revenue of 1.05B EGP in the quarter ending June 30, 2026, with 9.41% growth. This brings the company's total for the last twelve months to 4.39B, up 22.69% year-over-year. In the year 2025, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had annual revenue of 4.10B with 47.94% growth. That makes Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) the 24,231st largest company in the world by revenue and 76th in Egypt.

• Revenue (ttm): 4.39B
• Revenue Growth: +22.69%
• P/S Ratio: 2.41
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 10.57B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Sales of Pharmaceutical Products 3.81B 93.0%
• Services Toll Manufacturing 284.79M 7.0%

By Geography

Chart

• Egypt 3.85B 94.1%
• Export 243.55M 5.9%

Fiscal year ended Dec 31, 2025 See the full EGX:RMDA breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.10B	1.33B	47.94%
Dec 31, 2024	2.77B	846.34M	44.03%
Dec 31, 2023	1.92B	438.40M	29.54%
Dec 31, 2022	1.48B	237.52M	19.06%
Dec 31, 2021	1.25B	286.27M	29.81%

Data Source: S&P Global Market Intelligence Last updated: Aug 16, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error